What is MICROALGO INC WTS's earnings per share (EPS)?

MICROALGO INC WTS (VENAF) reported diluted earnings per share of $2.12 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MICROALGO INC WTS (VENAF) Financials

VENAF

FY2025 annual

Revenue $60.0M -20.3% YoY

Net Income $18.1M +149.0% YoY

EPS (Diluted) $2.12 YoY not available

Free Cash Flow $2.5M -39.1% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Apr 1, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Apr 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VENAF SEC filings page.

MICROALGO INC WTS (VENAF) reported $60.0M in revenue for fiscal year 2025, down 20.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VENAF FY2025 2026-10-03

VENAF’s shrinking operating business produced weak cash conversion, while expansion was funded mainly outside operations.

FY2025’s 30.2% net margin versus a 5.3% operating margin indicates a below-the-line lift, not stronger core operations. Operating cash flow of $2.5M nearly matched free cash flow of $2.5M, so the reported profit did not translate into comparable cash generation.

Revenue fell from $75.3M in FY2024 to $60.0M in FY2025, so the top line did not provide the growth engine behind the year’s earnings. Gross margin narrowed from 28.4% to 25.8%; with R&D also lower, the modest improvement in operating performance appears cost-led rather than demand-led.

Assets rose from $176.3M in FY2024 to $350.3M in FY2025, a balance-sheet expansion far larger than the change in operating earnings. Investing cash flow of -$121.8M alongside financing cash flow of $153.9M indicates that expansion was funded externally, while operating cash generation remained modest.

Financial Health Signals

Financial health score not available

MICROALGO INC WTS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/7

MICROALGO INC WTS passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.14x

For every $1 of reported earnings, MICROALGO INC WTS generates $0.14 in operating cash flow ($2.5M OCF vs $18.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

13.51x

MICROALGO INC WTS earns $13.51 in operating income for every $1 of interest expense ($3.2M vs $236K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$174.8M

YoY+21.3%

QoQ-31.0%

MICROALGO INC WTS held $174.8M in cash as of Q4 2025; long-term debt is not reported for that period.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Shares Outstanding

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

VENAF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VENAF quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	$60.0M-20.3%	$75.3M-8.0%	$81.9M-6.0%	$87.1M+6.2%	$82.0M	N/A
Cost of Revenue	$44.6M-17.4%	$53.9M-5.9%	$57.3M-15.9%	$68.2M+39.4%	$48.9M	N/A
Gross Profit	$15.5M-27.6%	$21.4M-12.9%	$24.6M+29.6%	$19.0M-42.8%	$33.1M+28215.9%	-$118K
R&D Expenses	$9.0M-42.1%	$15.5M-31.7%	$22.8M+63.4%	$13.9M-16.0%	$16.6M	N/A
SG&A Expenses	$3.0M+8.6%	$2.7M-21.9%	$3.5M-31.4%	$5.1M-2.8%	$5.3M	N/A
Operating Income	$3.2M+13.7%	$2.8M+108.1%	-$34.6M-340.4%	-$7.9M-197.7%	$8.0M	N/A
EBITDA	$3.4M+13.4%	$3.0M+108.9%	-$33.6M-418.1%	-$6.5M-168.0%	$9.5M	N/A
Interest Expense	$236K-93.7%	$3.7M+581.0%	$548K+106.1%	$266K-8.9%	$292K	N/A
Income Tax	$1.0M+22.2%	$854K+341.9%	-$353K+37.5%	-$565K-765.9%	$85K	N/A
Net Income	$18.1M+149.0%	$7.3M+119.4%	-$37.6M-439.7%	-$7.0M-181.3%	$8.6M+7374.1%	-$118K
EPS (Basic)	$2.12+45.2%	$1.46+117.6%	-$8.30	N/A	N/A	N/A
EPS (Diluted)	$2.12	$0.56	-$8.30	N/A	N/A	N/A
Diluted Shares (Avg)	8M	10M	22,810+14.5%	19,930	4M	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$17.8M-23.7%	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$12.9M-28.3%	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$5.0M-8.2%	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$5.2M+63.2%	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$1.0M+25.7%	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	-$1.4M-220.1%	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	-$1.3M-185.9%	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$4K-86.2%	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$5K-54.3%	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	-$1.3M-242.4%	N/A

Not reported in any period shown, so not listed: EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

VENAF Balance Sheet

VENAF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$350.3M+98.8%	$176.3M+204.1%	$58.0M-19.6%	$72.1M-11.7%	$81.6M+42507.6%	$192K
Current Assets	$350.1M+99.0%	$175.9M+205.2%	$57.6M+4.4%	$55.2M+2.2%	$54.0M+70652.7%	$76K
Cash & Equivalents	$174.8M+21.3%	$144.1M+221.8%	$44.8M+4.8%	$42.7M+0.1%	$42.7M+17874291.2%	$239
Short-Term Investments	$161.9M+678.1%	$20.8M+700.5%	$2.6M	$0	$0	$0
Inventory	N/A	N/A	N/A	$131K-84.2%	$824K	N/A
Accounts Receivable	$6.2M+88.0%	$3.3M+1.5%	$3.2M+24.8%	$2.6M-6.0%	$2.8M	N/A
Long-Term Investments	$14K	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	$15.3M-30.5%	$21.9M	N/A
Total Liabilities	$15.6M-46.1%	$28.9M+139.8%	$12.0M+137.3%	$5.1M-77.9%	$23.0M+7680.5%	$295K
Current Liabilities	$15.5M-46.0%	$28.8M+139.0%	$12.0M+150.8%	$4.8M-78.1%	$22.0M+7340.1%	$295K
Non-Current Liabilities	$34K-64.6%	$97K	$0-100.0%	$272K-72.9%	$1.0M	$0
Total Equity	$330.3M+127.9%	$144.9M+219.4%	$45.4M-32.0%	$66.8M+14.3%	$58.4M+56437.9%	-$104K
Retained Earnings	$11.4M+344.1%	-$4.7M+57.1%	-$10.9M-156.9%	$19.1M-27.7%	$26.5M+20683.7%	-$129K

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q
Total Assets	$350.3M+98.8%	$330.8M+207.5%	$176.3M+204.1%	$107.6M+49.8%	$58.0M-19.6%	$71.8M+51.7%	$75.6M+61.6%	$72.1M-11.7%
Current Assets	$350.1M+99.0%	$330.5M+208.0%	$175.9M+205.2%	$107.3M+92.1%	$57.6M+4.4%	$55.9M+137345.0%	$58.7M+204724.4%	$55.2M+2.2%
Cash & Equivalents	$174.8M+21.3%	$253.3M+316.5%	$144.1M+221.8%	$60.8M+216.9%	$44.8M+4.8%	$19.2M+175987.3%	$21.0M+73182.4%	$42.7M+0.1%
Short-Term Investments	$161.9M+678.1%	$66.1M+1028.2%	$20.8M+700.5%	$5.9M	$2.6M	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$131K-84.2%
Accounts Receivable	$6.2M+88.0%	$3.3M+8.5%	$3.3M+1.5%	$3.0M-42.0%	$3.2M+24.8%	$5.2M	$1.6M	$2.6M-6.0%
Long-Term Investments	$14K	$14K	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	$14.7M	$15.5M	$15.3M-30.5%
Total Liabilities	$15.6M-46.1%	$10.1M-66.8%	$28.9M+139.8%	$30.3M+155.0%	$12.0M+137.3%	$11.9M-76.4%	$8.7M-82.3%	$5.1M-77.9%
Current Liabilities	$15.5M-46.0%	$10.0M-66.9%	$28.8M+139.0%	$30.2M+160.1%	$12.0M+150.8%	$11.6M+682.5%	$8.4M+813.5%	$4.8M-78.1%
Non-Current Liabilities	$34K-64.6%	$54K-4.7%	$97K	$57K-77.5%	$0-100.0%	$252K-99.5%	$306K-99.4%	$272K-72.9%
Total Equity	$330.3M+127.9%	$317.6M+318.0%	$144.9M+219.4%	$76.0M+25.8%	$45.4M-32.0%	$60.4M+2105.2%	$66.7M+2807.5%	$66.8M+14.3%
Retained Earnings	$11.4M+344.1%	-$992K+88.4%	-$4.7M+57.1%	-$8.5M-159.3%	-$10.9M-156.9%	$14.4M+578.4%	$17.9M+825.9%	$19.1M-27.7%

Not reported in any period shown, so not listed: Long-Term Debt.

VENAF Cash Flow Statement

VENAF quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	$2.5M-39.1%	$4.1M+163.6%	-$6.4M-427.9%	$2.0M-87.2%	$15.3M+19726.6%	-$78K
Depreciation & Amortization	$197K+9.9%	$179K-82.3%	$1.0M-26.2%	$1.4M-7.6%	$1.5M	N/A
Stock-Based Compensation	N/A	N/A	$16.9M	N/A	N/A	N/A
Capital Expenditures	$1K-70.9%	$4K-60.9%	$10K-93.7%	$161K+346.9%	$36K	N/A
Free Cash Flow	$2.5M-39.1%	$4.1M+163.4%	-$6.4M-457.9%	$1.8M-88.2%	$15.2M	N/A
Investing Cash Flow	-$121.8M-602.7%	-$17.3M-634.5%	-$2.4M-185.4%	$2.8M+142.6%	-$6.5M-11788752.7%	-$55
Financing Cash Flow	$153.9M+36.8%	$112.5M+941.3%	$10.8M+546.1%	-$2.4M+37.0%	-$3.8M-999.0%	-$350K

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	-$3.8M-411.6%	-$2.8M-704.8%	$2.3M-85.4%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$107K-68.8%	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$11.5M+389409.9%	$54K-70.7%	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$15.3M-1941.2%	-$2.8M-1139.7%	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$481K	-$257K+98.4%	$4.1M-89.6%
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	$1.8M-69.2%	-$19.6M-255.7%	-$4.2M+91.8%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

VENAF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VENAF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	25.8%-2.6pp	28.4%-1.6pp	30.0%+8.2pp	21.8%-18.6pp	40.4%	N/A
Operating Margin	5.3%+1.6pp	3.7%+46.0pp	-42.3%-33.3pp	-9.0%-18.8pp	9.8%	N/A
Net Margin	30.2%+20.5pp	9.7%+55.6pp	-45.9%-37.9pp	-8.0%-18.4pp	10.4%	N/A
Return on Equity	5.5%+0.5pp	5.0%+87.9pp	-82.8%-72.4pp	-10.4%-25.1pp	14.7%	N/A
Return on Assets	5.2%+1.0pp	4.1%+69.0pp	-64.8%-55.2pp	-9.7%-20.2pp	10.5%+72.0pp	-61.5%
Current Ratio	22.53+16.4x	6.11+1.3x	4.79-6.7x	11.49+9.0x	2.46+2.2x	0.26
Debt-to-Equity	0.05-0.2x	0.20-0.1x	0.27+0.2x	0.08-0.3x	0.39	N/A
Asset Turnover	0.17-0.3x	0.43-1.0x	1.41+0.2x	1.21+0.2x	1.01	N/A
FCF Margin	4.1%-1.3pp	5.4%+13.3pp	-7.8%-9.9pp	2.1%-16.5pp	18.6%	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	27.8%+4.7pp	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-7.9%-13.0pp	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-7.1%-10.9pp	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	-1.9%	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	-1.7%-3.6pp	N/A
Current Ratio	22.53+16.4x	33.05+29.5x	6.11+1.3x	3.55-1.3x	4.79-6.7x	4.81+4.8x	6.98+6.9x	11.49+9.0x
Debt-to-Equity	0.05-0.2x	0.03-0.4x	0.20-0.1x	0.40+0.2x	0.27+0.2x	0.20	0.13	0.08-0.3x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.24-0.3x	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-15.8%-17.0pp	N/A

Where MICROALGO INC WTS Ranks

Frequently Asked Questions

What is MICROALGO INC WTS's annual revenue?

MICROALGO INC WTS (VENAF) reported $60.0M in total revenue for fiscal year 2025. This represents a -20.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MICROALGO INC WTS's revenue growing?

MICROALGO INC WTS (VENAF) revenue declined by 20.3% year-over-year, from $75.3M to $60.0M in fiscal year 2025.

Is MICROALGO INC WTS profitable?

Yes, MICROALGO INC WTS (VENAF) reported a net income of $18.1M in fiscal year 2025, with a net profit margin of 30.2%.

What is MICROALGO INC WTS's EBITDA?

MICROALGO INC WTS (VENAF) had EBITDA of $3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is MICROALGO INC WTS's gross margin?

MICROALGO INC WTS (VENAF) had a gross margin of 25.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is MICROALGO INC WTS's operating margin?

MICROALGO INC WTS (VENAF) had an operating margin of 5.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is MICROALGO INC WTS's net profit margin?

MICROALGO INC WTS (VENAF) had a net profit margin of 30.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is MICROALGO INC WTS's return on equity (ROE)?

MICROALGO INC WTS (VENAF) has a return on equity of 5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is MICROALGO INC WTS's free cash flow?

MICROALGO INC WTS (VENAF) generated $2.5M in free cash flow during fiscal year 2025. This represents a -39.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is MICROALGO INC WTS's operating cash flow?

MICROALGO INC WTS (VENAF) generated $2.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are MICROALGO INC WTS's total assets?

MICROALGO INC WTS (VENAF) had $350.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are MICROALGO INC WTS's capital expenditures?

MICROALGO INC WTS (VENAF) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does MICROALGO INC WTS spend on research and development?

MICROALGO INC WTS (VENAF) invested $9.0M in research and development during fiscal year 2025.

What is MICROALGO INC WTS's current ratio?

MICROALGO INC WTS (VENAF) had a current ratio of 22.53 as of fiscal year 2025, which is generally considered healthy.

What is MICROALGO INC WTS's debt-to-equity ratio?

MICROALGO INC WTS (VENAF) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is MICROALGO INC WTS's return on assets (ROA)?

MICROALGO INC WTS (VENAF) had a return on assets of 5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is MICROALGO INC WTS's Piotroski F-Score?

MICROALGO INC WTS (VENAF) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MICROALGO INC WTS's earnings high quality?

MICROALGO INC WTS (VENAF) has an earnings quality ratio of 0.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can MICROALGO INC WTS cover its interest payments?

MICROALGO INC WTS (VENAF) has an interest coverage ratio of 13.51x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.